Court Documents Reveal that Lawsuits Continue to Mount in Lipitor MDL in the United States District Court, District of South Carolina, Parker Waichman Comments

Share Article

Lawsuits allege that the statin, Lipitor, caused plaintiffs to develop adverse reactions, including Type 2 diabetes.

News Image
Whenever we see these types of associations, we become concerned for the health of patients seeking treatment for one problem who may be putting themselves at risk for another problem.

Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of consumers who have suffered injuries due to dangerous drugs, comments on the addition of more than 100 new lawsuits filed last month in the federal litigation in the U.S. District Court, District of South Carolina. The case is In Re: Lipitor (Atorvastatin) Litigation, MDL No. 2502 and involves allegations that Lipitor led to plaintiffs developing Type 2 diabetes.

The case list for this MDL reveals that actions involving Lipitor are mounting, rising from 1,478 as of December 15, 2014 to 1,604 as of January 15, 2015, according to court documents. The lawsuits similarly allege that Pfizer Inc. hid details about Lipitor’s association with diabetes and that plaintiffs would not have accepted Lipitor treatment, or would have asked for closer diabetes monitoring, had they been aware of these risks and had Pfizer fully revealed this information. The lawsuit further claims that Pfizer marketed Lipitor without adequate warnings or instructions. A conference was also recently held on January 22, 2015 in the multidistrict litigation (MDL) brought over the statin drug, Lipitor.

“We are pleased to see this litigation continue to move forward,” says Gary Falkowitz, Managing Attorney at Parker Waichman. “Patients and physicians rely on safe and effective medical treatments and patients and doctors need to know whether, and to what extent, certain types of treatments may present serious adverse reactions.”

The cholesterol-lowering medication, Lipitor, has been associated with increased risks for cataracts, as well, according to a December
4, 2014 report issued by HealthDay News. The report indicated that a cohort study published in the Canadian Journal of Cardiology revealed that use of statins, such as Lipitor, may possibly increase risks for developing cataracts if taken for at least one year; the team called for additional research.

“Whenever we see these types of associations, we become concerned for the health of patients seeking treatment for one problem who may be putting themselves at risk for another problem. We are pleased that the Canadian researchers have called for additional research on any possible associations between statins and ocular issues,” said Gary Falkowitz, Managing Attorney at Parker Waichman LLP.

Other research has tied the use of statins, such as Lipitor, to increased risks for other serious adverse reactions. A study published in Clinical Endocrinology in November 2014 revealed that statins such as Lipitor may significantly increase women’s risks for developing thyroid cancer.

Meanwhile, the U.S. Food and Drug Administration(FDA) issued Safety Information on February 28, 2012 regarding an update to the drug’s label to include the serious increased risk of developing memory loss and confusion.

Parker Waichman LLP offers free lawsuit consultations to victims of statins, such as Lipitor. If you or a loved one experienced complications following Lipitor treatment, or treatment with any statin, please visit the firm’s Defective Drug page. Free case evaluations are also available by calling 1-800-LAW-INFO.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Falkowitz
Follow us on
Visit website